There have been remarkable advances recently in the treatment of patients with metastatic melanoma, including the development of inhibitors to immune checkpoint proteins and targeted therapies against the protein kinases BRAF and MEK. The gene discussed is MAP2K7; the disease is metastatic melanoma.